Method for inhibiting bone loss using centchroman derivatives
    3.
    发明授权
    Method for inhibiting bone loss using centchroman derivatives 失效
    使用间苯二酚衍生物抑制骨丢失的方法

    公开(公告)号:US5464862A

    公开(公告)日:1995-11-07

    申请号:US180728

    申请日:1994-01-13

    CPC分类号: A61K31/35 A61K31/40

    摘要: Methods and pharmaceutical compositions for reducing bone loss are disclosed. 3,4-diarylchromans and their pharmaceutically acceptable salts are formulated into medicaments for the treatment of bone loss due to osteoporosis or other conditions. An exemplary 3,4-diarylchroman is centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-[p-(beta-pyrrolidinoethoxy)phenyl]-7-methoxychroman). Formulations include tablets and other forms suitable for oral administration and controlled-release subdermal implants.

    摘要翻译: 公开了减少骨丢失的方法和药物组合物。 将3,4-二芳基苯并二氢吡喃及其药学上可接受的盐配制成用于治疗由骨质疏松症或其他病症引起的骨丢失的药物。 示例性3,4-二芳基苯并二氢吡喃是中性苯并二氢吡喃(3,4-反式-2,2-二甲基-3-苯基-4- [对 - (β-吡咯烷基)乙氧基)苯基] -7-甲氧基苯并二氢吡喃)。 制剂包括适于口服给药和受控释放的皮下植入物的片剂和其它形式。

    Methods for reducing bone loss using centchroman derivatives
    4.
    发明授权
    Methods for reducing bone loss using centchroman derivatives 失效
    使用分散染料衍生物减少骨丢失的方法

    公开(公告)号:US5280040A

    公开(公告)日:1994-01-18

    申请号:US29729

    申请日:1993-03-11

    CPC分类号: A61K31/35 A61K31/40

    摘要: Methods and pharmaceutical compositions for reducing bone loss are disclosed. 3,4-diarylchromans and their pharmaceutically acceptable salts are formulated into medicaments for the treatment of bone loss due to osteoporosis or other conditions. An exemplary 3,4-diarylchroman is centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-[p-(beta-pyrrolidinoethoxy)phenyl]-7-methoxy-chroman). Formulations include tablets and other forms suitable for oral administration and controlled-release subdermal implants.

    摘要翻译: 公开了减少骨丢失的方法和药物组合物。 将3,4-二芳基苯并二氢吡喃及其药学上可接受的盐配制成用于治疗由骨质疏松症或其他病症引起的骨丢失的药物。 示例性的3,4-二芳基苯并二氢吡喃是中性色满(3,4-反式-2,2-二甲基-3-苯基-4-(对 - (β-吡咯烷基乙氧基)苯基)-7-甲氧基 - 苯并二氢吡喃)。 制剂包括适于口服给药和受控释放的皮下植入物的片剂和其它形式。

    Methods for treatment and prevention of bone loss using 2,3-benzopyrans
    7.
    发明授权
    Methods for treatment and prevention of bone loss using 2,3-benzopyrans 失效
    使用2,3-苯并吡喃治疗和预防骨丢失的方法

    公开(公告)号:US5389646A

    公开(公告)日:1995-02-14

    申请号:US175899

    申请日:1993-12-30

    CPC分类号: A61K31/35 A61K31/445

    摘要: Methods and pharmaceutical compositions for reducing bone loss are disclosed. 2,3-diaryl-1-benzopyrans and their pharmaceutically acceptable salts are formulated into medicaments for the treatment of bone loss due to osteoporosis or other conditions. Formulations include tablets and other forms suitable for oral administration and controlled-release subdermal implants.

    摘要翻译: 公开了减少骨丢失的方法和药物组合物。 将2,3-二芳基-1-苯并吡喃及其药学上可接受的盐配制成用于治疗骨质疏松症或其他病症引起的骨丢失的药物。 制剂包括适于口服给药和受控释放的皮下植入物的片剂和其它形式。

    Isoprenoid pathway inhibitors for stimulating bone growth
    8.
    发明授权
    Isoprenoid pathway inhibitors for stimulating bone growth 有权
    用于刺激骨生长的异戊二醛途径抑制剂

    公开(公告)号:US06642216B2

    公开(公告)日:2003-11-04

    申请号:US09848839

    申请日:2001-05-03

    IPC分类号: A61K31665

    摘要: Compounds of the formula wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C; Y is of the formula  or a stereoisomer thereof, wherein R1 is substituted or unsubstituted alkyl; each R2 is independently H, hydroxy, alkoxy (1-6C) or lower alkyl (1-4C); R3 is H, hydroxy, or alkoxy (1-6C); or Y is of the formula  wherein each n is 1, Z is N, K comprises a substituted or unsubstituted aromatic carbocyclic or heterocyclic ring system which may optionally be spaced from the linkage position shown in formula (7) by a linker of 1-2C, or in formula (7), Z may be spaced from the carbon bonded to X by ═CR6— wherein R6 is H or linear, branded or cyclic alkyl (1-6C), R5 is H or linear, branched or cyclic alkyl, and R′ represents a cation, H or a substituted or unsubstituted alkyl group of 1-6C, promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation. Also disclosed is a method to identify additional compounds which are inhibitors of enzymes in the isoprenoid scheme especially of HMG-CoA reductase which results in prenylation of proteins and in the synthesis of steroids or of inhibitors of their production which are useful in treating bone disorders.

    摘要翻译: 式(1)和(2)中的式(Ⅳ)化合物表示取代或未取代的2-6C的亚烷基,亚烯基或亚炔基接头; Y为其立体异构体,其中R 1为取代或 每个R 2独立地是H,羟基,烷氧基(1-6C)或低级烷基(1-4C); R 3是H,羟基或烷氧基(1-6C); 或Y是每个n是1的烷基,其中Z是N,K包括取代或未取代的芳族碳环或杂环系统,其可以任选地与式(7)所示的连接位置与1-2C的连接体间隔开,或 在式(7)中,Z可以与通过= CR 6键合到X的碳隔开,其中R 6是H或直链的,有品牌的或环状的烷基(1-6C),R 5是H或 直链,支链或环状的烷基,R'表示1-6个C的阳离子H或取代或未取代的烷基,促进骨形成,因此可用于治疗骨质疏松症,骨折或缺陷,原发性或继发性甲状旁腺功能亢进,牙周病或 缺损,转移性骨病,溶骨性骨病,整形后手术,假体后关节手术和牙后植入术。还公开了一种鉴定作为特异性HMG-CoA的异戊二烯方案中的酶抑制剂的其它化合物的方法 导致蛋白质异戊烯化的还原酶 在合成类固醇或其制备的抑制剂中可用于治疗骨骼疾病。

    Combinatorial non-peptide libraries
    9.
    发明授权
    Combinatorial non-peptide libraries 失效
    组合非肽库

    公开(公告)号:US5646285A

    公开(公告)日:1997-07-08

    申请号:US483496

    申请日:1995-06-07

    摘要: The present invention relates to an orthogonally-protected compound of the formula: ##STR1## wherein PG.sub.1 is a first protecting group that is unreactive to a chemistry used at another position within the compound, and that is capable of selective removal without affecting PG.sub.2 or linkage to a solid support; PG.sub.2 is a second protecting group that is unreactive to a chemistry used at another position within the compound, and that is capable of selective removal without affecting PG.sub.1 or linkage to a solid support; Y is CH.sub.2 COOH, CH.sub.2 SO.sub.2 OH, CH.sub.2 PO.sub.2 ROH, CH.sub.2 Ph--COOH, CH.sub.2 Ph--SO.sub.2 OH, or CH.sub.2 Ph--PO.sub.2 ROH; R is H or a substituted or unsubstituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; and n is 1 or 2. PG.sub.1 is preferably a carbamate group, a trityl group, or a trifluoroacetyl group; and PG.sub.2 is preferably an ester.

    摘要翻译: 本发明涉及具有下式的正交保护的化合物:其中PG1是对化合物中另一位置使用的化学物质不起反应的第一保护基,并且能够在没有 影响PG2或与固体支持物的连接; PG2是与在化合物中另一位置使用的化学物质不反应的第二保护基团,并且能够选择性去除而不影响PG1或与固体支持物的连接; Y是CH 2 COOH,CH 2 SO 2 OH,CH 2 PO2ROH,CH 2 Ph-COOH,CH 2 Ph-SO 2 OH或CH 2 Ph-PO 2 ROH; R是H或取代或未取代的烷基,环烷基,芳基,芳基烷基,杂芳基或杂芳基烷基; 并且n为1或2.PG1优选为氨基甲酸酯基,三苯甲基或三氟乙酰基; PG2优选为酯。

    Thionated analogues of thyrotropin releasing hormone
    10.
    发明授权
    Thionated analogues of thyrotropin releasing hormone 失效
    Throtated类似物的促甲状腺激素释放激素

    公开(公告)号:US5244884A

    公开(公告)日:1993-09-14

    申请号:US963026

    申请日:1992-10-19

    IPC分类号: A61K38/00 C07K5/097

    CPC分类号: C07K5/0821 A61K38/00

    摘要: There are disclosed thionated analogues of thyrotropin releasing hormone, having the formula: ##STR1## wherein, Q, W, X and Y, same or different, are oxygen or sulfur, with the proviso that at least one of Q, W, X and Y is always sulfur;Z is lower alkyl or (4-imidazolyl)methyl; and the pharmaceutically acceptable salts thereof. The disclosed compounds highly and selectively bind to TRH binding sites in animal tissues, and their utility in treating a variety of diverse physical conditions is disclosed. Pharmaceutical compositions containing the compounds are also disclosed.

    摘要翻译: 公开了具有以下分子式的促甲状腺激素释放激素的分解类似物:其中Q,W,X和Y相同或不同,是氧或硫,条件是Q,W,X和 Y总是硫; Z是低级烷基或(4-咪唑基)甲基; 及其药学上可接受的盐。 所公开的化合物高度和选择性地结合动物组织中的TRH结合位点,并且其在治疗各种各样的物理条件中的用途被公开。 还公开了含有这些化合物的药物组合物。